A detailed history of Alpha Mark Advisors, LLC transactions in Catalent, Inc. stock. As of the latest transaction made, Alpha Mark Advisors, LLC holds 100 shares of CTLT stock, worth $6,098. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100
Previous 150 33.33%
Holding current value
$6,098
Previous $8,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$56.16 - $60.96 $2,808 - $3,048
-50 Reduced 33.33%
100 $6,000
Q2 2024

Jul 17, 2024

SELL
$53.58 - $57.02 $2,679 - $2,851
-50 Reduced 25.0%
150 $8,000
Q1 2024

Apr 18, 2024

SELL
$42.56 - $59.82 $2,128 - $2,991
-50 Reduced 20.0%
200 $11,000
Q3 2023

Oct 31, 2023

SELL
$44.2 - $50.2 $6,188 - $7,028
-140 Reduced 35.9%
250 $11,000
Q2 2023

Jul 28, 2023

BUY
$31.86 - $67.26 $1,274 - $2,690
40 Added 11.43%
390 $17,000
Q1 2023

May 04, 2023

BUY
$45.44 - $74.26 $15,904 - $25,991
350 New
350 $23,000

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $11B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Alpha Mark Advisors, LLC Portfolio

Follow Alpha Mark Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Mark Advisors, LLC with notifications on news.